Furthermore, a TGM2 inhibitor reduced the Rb1;Trp53 tumor organoid–derived liver NEPC burden, and Tgm2–/– recipient mice exhibited substantially reduced liver NEPC compared with Tgm2 wild-type mice (7). This evidence concerns the gene TP53 and neoplasm.